new

Get trending papers in your email inbox!

Subscribe

byAK and the research community

Mar 11

ShaSTA-Fuse: Camera-LiDAR Sensor Fusion to Model Shape and Spatio-Temporal Affinities for 3D Multi-Object Tracking

3D multi-object tracking (MOT) is essential for an autonomous mobile agent to safely navigate a scene. In order to maximize the perception capabilities of the autonomous agent, we aim to develop a 3D MOT framework that fuses camera and LiDAR sensor information. Building on our prior LiDAR-only work, ShaSTA, which models shape and spatio-temporal affinities for 3D MOT, we propose a novel camera-LiDAR fusion approach for learning affinities. At its core, this work proposes a fusion technique that generates a rich sensory signal incorporating information about depth and distant objects to enhance affinity estimation for improved data association, track lifecycle management, false-positive elimination, false-negative propagation, and track confidence score refinement. Our main contributions include a novel fusion approach for combining camera and LiDAR sensory signals to learn affinities, and a first-of-its-kind multimodal sequential track confidence refinement technique that fuses 2D and 3D detections. Additionally, we perform an ablative analysis on each fusion step to demonstrate the added benefits of incorporating the camera sensor, particular for small, distant objects that tend to suffer from the depth-sensing limits and sparsity of LiDAR sensors. In sum, our technique achieves state-of-the-art performance on the nuScenes benchmark amongst multimodal 3D MOT algorithms using CenterPoint detections.

Learning dynamic representations of the functional connectome in neurobiological networks

The static synaptic connectivity of neuronal circuits stands in direct contrast to the dynamics of their function. As in changing community interactions, different neurons can participate actively in various combinations to effect behaviors at different times. We introduce an unsupervised approach to learn the dynamic affinities between neurons in live, behaving animals, and to reveal which communities form among neurons at different times. The inference occurs in two major steps. First, pairwise non-linear affinities between neuronal traces from brain-wide calcium activity are organized by non-negative tensor factorization (NTF). Each factor specifies which groups of neurons are most likely interacting for an inferred interval in time, and for which animals. Finally, a generative model that allows for weighted community detection is applied to the functional motifs produced by NTF to reveal a dynamic functional connectome. Since time codes the different experimental variables (e.g., application of chemical stimuli), this provides an atlas of neural motifs active during separate stages of an experiment (e.g., stimulus application or spontaneous behaviors). Results from our analysis are experimentally validated, confirming that our method is able to robustly predict causal interactions between neurons to generate behavior. Code is available at https://github.com/dyballa/dynamic-connectomes.

Molecular Graph Generation via Geometric Scattering

Graph neural networks (GNNs) have been used extensively for addressing problems in drug design and discovery. Both ligand and target molecules are represented as graphs with node and edge features encoding information about atomic elements and bonds respectively. Although existing deep learning models perform remarkably well at predicting physicochemical properties and binding affinities, the generation of new molecules with optimized properties remains challenging. Inherently, most GNNs perform poorly in whole-graph representation due to the limitations of the message-passing paradigm. Furthermore, step-by-step graph generation frameworks that use reinforcement learning or other sequential processing can be slow and result in a high proportion of invalid molecules with substantial post-processing needed in order to satisfy the principles of stoichiometry. To address these issues, we propose a representation-first approach to molecular graph generation. We guide the latent representation of an autoencoder by capturing graph structure information with the geometric scattering transform and apply penalties that structure the representation also by molecular properties. We show that this highly structured latent space can be directly used for molecular graph generation by the use of a GAN. We demonstrate that our architecture learns meaningful representations of drug datasets and provides a platform for goal-directed drug synthesis.

Beyond Uniform Query Distribution: Key-Driven Grouped Query Attention

The Transformer architecture has revolutionized deep learning through its Self-Attention mechanism, which effectively captures contextual information. However, the memory footprint of Self-Attention presents significant challenges for long-sequence tasks. Grouped Query Attention (GQA) addresses this issue by grouping queries and mean-pooling the corresponding key-value heads - reducing the number of overall parameters and memory requirements in a flexible manner without adversely compromising model accuracy. In this work, we introduce enhancements to GQA, focusing on two novel approaches that deviate from the static nature of grouping: Key-Distributed GQA (KDGQA) and Dynamic Key-Distributed GQA (DGQA), which leverage information from the norms of the key heads to inform query allocation. Specifically, KDGQA looks at the ratios of the norms of the key heads during each forward pass, while DGQA examines the ratios of the norms as they evolve through training. Additionally, we present Perturbed GQA (PGQA) as a case-study, which introduces variability in (static) group formation via subtracting noise from the attention maps. Our experiments with up-trained Vision Transformers, for Image Classification on datasets such as CIFAR-10, CIFAR-100, Food101, and Tiny ImageNet, demonstrate the promise of these variants in improving upon the original GQA through more informed and adaptive grouping mechanisms: specifically ViT-L experiences accuracy gains of up to 8% when utilizing DGQA in comparison to GQA and other variants. We further analyze the impact of the number of Key-Value Heads on performance, underscoring the importance of utilizing query-key affinities. Code is available on GitHub.

DrugGen: Advancing Drug Discovery with Large Language Models and Reinforcement Learning Feedback

Traditional drug design faces significant challenges due to inherent chemical and biological complexities, often resulting in high failure rates in clinical trials. Deep learning advancements, particularly generative models, offer potential solutions to these challenges. One promising algorithm is DrugGPT, a transformer-based model, that generates small molecules for input protein sequences. Although promising, it generates both chemically valid and invalid structures and does not incorporate the features of approved drugs, resulting in time-consuming and inefficient drug discovery. To address these issues, we introduce DrugGen, an enhanced model based on the DrugGPT structure. DrugGen is fine-tuned on approved drug-target interactions and optimized with proximal policy optimization. By giving reward feedback from protein-ligand binding affinity prediction using pre-trained transformers (PLAPT) and a customized invalid structure assessor, DrugGen significantly improves performance. Evaluation across multiple targets demonstrated that DrugGen achieves 100% valid structure generation compared to 95.5% with DrugGPT and produced molecules with higher predicted binding affinities (7.22 [6.30-8.07]) compared to DrugGPT (5.81 [4.97-6.63]) while maintaining diversity and novelty. Docking simulations further validate its ability to generate molecules targeting binding sites effectively. For example, in the case of fatty acid-binding protein 5 (FABP5), DrugGen generated molecules with superior docking scores (FABP5/11, -9.537 and FABP5/5, -8.399) compared to the reference molecule (Palmitic acid, -6.177). Beyond lead compound generation, DrugGen also shows potential for drug repositioning and creating novel pharmacophores for existing targets. By producing high-quality small molecules, DrugGen provides a high-performance medium for advancing pharmaceutical research and drug discovery.